您好,欢迎来到试剂仪器网! [登录] [免费注册]
试剂仪器网
位置:首页 > 产品库 > Vonoprazan Fumarate(TAK-438)
立即咨询
咨询类型:
     
*姓名:
*电话:
*单位:
Email:
*留言内容:
请详细说明您的需求。
*验证码:
 
Vonoprazan Fumarate(TAK-438)
本产品不向个人销售,仅用作科学研究,不用于任何人体实验及非科研性质的动物实验。
Vonoprazan Fumarate(TAK-438)图片
CAS NO:1260141-27-2
规格:≥98%
包装与价格:
包装价格(元)
100mg电议
250mg电议
500mg电议
1g电议
2g电议

产品介绍
Vonoprazan Fumarate (formerly TAK-438, TAK 438, trade name Takecab), the fumarate salt of Vonoprazan, is a novel, orally bioactive and potent P-CAB (potassium-competitive acid blocker) that has been approved in Janpan in 2015 for the treatment of gastroduodenal ulcer and reflux esophagitis. It acts by reversibly inhibiting H+/K+, ATPase with an IC50 of 19 nM (pH 6.5), controls gastric acid secretion. In cultured gastric glands, TAK-438 treatment resulted in a longer and stronger acid formation inhibition. The inhibition effect of TAK-438 on acid secretion seemed to be associated with gastric parietal cell physiology.
理化性质和储存条件
Molecular Weight (MW)461.46
FormulaC17H16FN3O2S.C4H4O4
CAS No.1260141-27-2 (fumarate);
Storage-20℃ for 3 years in powder form
-80℃ for 2 years in solvent
Solubility (In vitro)DMSO: 62 mg/mL (134.4 mM)
Water:<1 mg/mL
Ethanol:<1 mg/mL
Solubility (In vivo)0.5% methylcellulose: 17 mg/mL
SynonymsTAK438, Vonoprazan Fumarate, TAK-438, TAK 438, Takecab
实验参考方法
In Vitro

In vitro activity: TAK-438 is a pyrrole derivative with a chemical structure that is completely different from the P-CABs developed to date. TAK-438 inhibits gastric H+, K+-ATPase activity in a concentration-dependent manner. Under neutral conditions (pH 7.5), the inhibitory activity of TAK-438 is almost the same as that under weakly acidic conditions (pH 6.5). TAK-438 does not inhibit Na+, K+-ATPase activity even at concentration 500 times higher than their IC50 values against gastric H+,K+-ATPase activity. TAK-438 inhibits gastric H+, K+-ATPase in a K+-competitive manner with Ki of 3 nM.


Kinase Assay: Vonoprazan (TAK-438 free base) is an orally active potassium-competitive acid blocker which inhibits H+, K+-ATPase activity with an IC50 of 19 nM.

In VivoTAK-438 inhibits basal gastric acid secretion in a dose-dependent manner, and the ID50 value is 1.26 mg/kg . Intravenous administration of TAK-438 dose-dependently increases the pH of the gastric perfusate, and the increase in pH is sustained for 5 h after administration. At the 1 mg/kg dose, the pH plateaues 90 min after administration, and the highest pH value reached is 5.9. In addition, TAK-438 shows a potent and longer-lasting inhibitory effect on the histamine-stimulated gastric acid secretion in rats and dogs. TAK-438 shows significant antisecretory activity through high accumulation and slow clearance from the gastric tissue. TAK-438 is unaffected by the gastric secretory state, unlike PPIs.
Animal modelMale Sprague-Dawley rats
Formulation & DosageDissolved in 0.5% methylcellulose solution; 1, 2, and 4 mg/kg; oral administration
ReferencesJ Pharmacol Exp Ther. 2010 Oct;335(1):231-8; J Pharmacol Exp Ther. 2011 Jun;337(3):797-804.